{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:11:05Z","timestamp":1792177865223,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001416.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000}}],"reference-count":42,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001416.pub4","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T12:46:46Z","timestamp":1539866806000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Zonisamide add-on therapy for focal epilepsy"],"prefix":"10.1002","author":[{"given":"Francesco","family":"Brigo","sequence":"first","affiliation":[{"name":"University of Verona; Department of Neurosciences, Biomedicine and Movement Sciences; P.le L.A. Scuro, 10 Verona Verona Italy 37134"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[{"name":"Marche Polytechnic University; Neurological Clinic; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C","family":"Igwe","sequence":"additional","affiliation":[{"name":"Federal Teaching Hospital; Department of Neuropsychiatry; Abakaliki Ebonyi State Nigeria 48000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Behzadifar","sequence":"additional","affiliation":[{"name":"Lorestan University of Medical Sciences; Social Determinants of Health Research Center; Khorramabad Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Luigi","family":"Bragazzi","sequence":"additional","affiliation":[{"name":"Postgraduate School of Public Health; Department of Health Sciences; University of Genoa Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"issue":"Suppl 7","key":"10.1002\/14651858.CD001416.pub4-BIB0001|cit1","first-page":"131, Abstract n","article-title":"Dose-dependent safety and efficacy of zonisamide in refractory, localization-related epilepsy: a randomized, double-blind, placebo-controlled trial","volume":"45","author":"Brodie","year":"2004","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001416.pub4-BIB0002|cit2","first-page":"155, Abstract n","article-title":"Zonisamide is a effective adjunctive therapy for patients with refractory partial epilepsy: results from a randomised, double-blind, placebo-controlled study","volume":"45","author":"Brodie","year":"2004","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD001416.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.0013-9580.2005.14704.x","article-title":"Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD001416.pub4-BIB0004|cit4","first-page":"117-8, Abstract","article-title":"Efficacy of zonisamide against refractory partial seizures in an evaluable patient population","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"issue":"10","key":"10.1002\/14651858.CD001416.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/WNL.57.10.1774","article-title":"Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures","volume":"57","author":"Faught","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD001416.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/epi.12233","article-title":"A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy","volume":"54","author":"Guerrini","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001416.pub4-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/11539750-000000000-00000","article-title":"Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy","volume":"31","author":"Lu","year":"2011","journal-title":"Clinical Drug Investigation"},{"issue":"6","key":"10.1002\/14651858.CD001416.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.0013-9580.2004.11403.x","article-title":"Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures","volume":"45","author":"Sackellares","year":"2004","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0009|cit9","unstructured":"Wilder BJ Ramsay RE Guterman A A double blind multicenter placebo controlled study of the efficacy of zonisamide in the treatment of complex partial seizures in medically refractory patients Internal report of the Dainippon Pharmaceutical Company 1986"},{"issue":"1","key":"10.1002\/14651858.CD001416.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0920-1211(93)90011-U","article-title":"Zonisamide for add-on treatment of refractory partial epilepsy: a European double blind trial","volume":"15","author":"Schmidt","year":"1993","journal-title":"Epilepsy Research"},{"issue":"7","key":"10.1002\/14651858.CD001416.pub4-BIB0011|cit11","first-page":"459","article-title":"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of zonisamide as adjunctive treatment in patients with refractory partial seizures","volume":"43","author":"Wu","year":"2010","journal-title":"Chinese Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001416.pub4-BIB0012|cit12","first-page":"408","article-title":"The efficacy and safety of zonisamide as adjunctive therapy in patients with partial seizure: A multicenter, randomized, double-blinded, placebo-controlled trial","volume":"11","author":"Zhang","year":"2011","journal-title":"Chinese Journal of Contemporary Neurology and Neurosurgery"},{"issue":"3","key":"10.1002\/14651858.CD001416.pub4-BIB0013|cit13","first-page":"583","article-title":"The antiepileptic effect of zonisamide on patients with refractory seizures and its side effects","volume":"42","author":"Shimizu","year":"1988","journal-title":"Japanese Journal of Psychiatry and Neurology"},{"issue":"854","key":"10.1002\/14651858.CD001416.pub4-BIB0014|cit14","first-page":"611","article-title":"Zonisamide: comparison with sodium valproate as additional treatment in refractory seizures","volume":"101","author":"Anderson","year":"1988","journal-title":"New Zealand Medical Journal"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0015|cit15","unstructured":"NCT00327717 Evaluating the efficacy and safety of zonisamide in the treatment of partial seizures clinicaltrials.gov\/ct2\/show\/NCT00327717"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0016|cit16","unstructured":"NCT01546688 A study to evaluate the safety and tolerability and explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial seizures clinicaltrials.gov\/ct2\/show\/NCT01546688"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eplepsyres.2007.04.007","article-title":"Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures","volume":"75","author":"Baulac","year":"2007","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0018|cit18","unstructured":"British National Formulary (BNF) www.bnf.org (accessed May 2013)"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001416.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1740774508091600","article-title":"Imputation methods for missing outcome data in meta-analysis of clinical trials","volume":"5","author":"Higgins","year":"2008","journal-title":"Clin Trials"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0022|cit22","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD001416.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0024|cit24","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","article-title":"Zonisamide: chemistry, mechanism of action, and pharmacokinetics","volume":"S13","author":"Leppik","year":"2004","journal-title":"Seizure"},{"issue":"3","key":"10.1002\/14651858.CD001416.pub4-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy","author":"Marson","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001416.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0920-1211(01)00287-X","article-title":"Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review","volume":"46","author":"Marson","year":"2001","journal-title":"Epilepsy Research"},{"issue":"9566","key":"10.1002\/14651858.CD001416.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0029|cit29","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0920-1211(97)00097-1","article-title":"The anticonvulsant zonisamide scavenges free radicals","volume":"30","author":"Mori","year":"1998","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0031|cit31","first-page":"38","article-title":"Zonisamide efficacy and dose response","volume":"38 Suppl 8","author":"Padgett","year":"1997","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD001416.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp.61.5.433","article-title":"Epidemiology of the epilepsies","volume":"61","author":"Sander","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001416.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0034|cit34","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Cochrane Applicability and Recommendations Methods Group Chapter 12 Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0035|cit35","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editor(s) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"1-2","key":"10.1002\/14651858.CD001416.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","article-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures","volume":"116","author":"Ueda","year":"2003","journal-title":"Molecular Brain Research"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0037|cit37","unstructured":"Wilder BJ Ramsay RE Guterman A Double blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients Internal Report of the Dianippon Pharmaceutical Co 1986"},{"issue":"12","key":"10.1002\/14651858.CD001416.pub4-BIB0038|cit38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001416.pub3","article-title":"Zonisamide add-on for drug-resistant partial epilepsy","author":"Carmichael","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001416.pub4-BIB0039|cit39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001416","article-title":"Zonisamide add-on for drug-resistant partial epilepsy","author":"Chadwick","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001416.pub4-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001416.pub2","article-title":"Zonisamide add-on for drug-resistant partial epilepsy","author":"Chadwick","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001416.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD001416.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001416.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001416.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:02:46Z","timestamp":1628542966000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001416.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001416.pub4","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001416.pub5","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]}}}